About Geranylgeranyl transferase type-1 subunit beta
Geranylgeranyl transferase type-1 subunit beta (PGGT1B) is a protein
from Homo sapiens identified by UniProt accession
P53609, 377 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Geranylgeranyl transferase type-1 subunit beta |
| UniProt accession | P53609 |
| Gene | PGGT1B |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (62)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- gestational diabetes · score 0.12
- cardiac arrhythmia · score 0.10
- chronic obstructive pulmonary disease · score 0.10
- cardioembolic stroke · score 0.08
- diastolic blood pressure · score 0.07
- systolic blood pressure · score 0.06
- age at diagnosis · score 0.06
- essential hypertension · score 0.06
- melanoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P53609-F1 | alphafold | PREDICTED | 94.38 | — |
Amino-acid sequence (377 residues)
MAATEDERLA GSGEGERLDF LRDRHVRFFQ RCLQVLPERY SSLETSRLTI AFFALSGLDM LDSLDVVNKD DIIEWIYSLQ VLPTEDRSNL NRCGFRGSSY LGIPFNPSKA PGTAHPYDSG HIAMTYTGLS CLVILGDDLS RVNKEACLAG LRALQLEDGS FCAVPEGSEN DMRFVYCASC ICYMLNNWSG MDMKKAITYI RRSMSYDNGL AQGAGLESHG GSTFCGIASL CLMGKLEEVF SEKELNRIKR WCIMRQQNGY HGRPNKPVDT CYSFWVGATL KLLKIFQYTN FEKNRNYILS TQDRLVGGFA KWPDSHPDAL HAYFGICGLS LMEESGICKV HPALNVSTRT SERLLDLHQS WKTKDSKQCS ENVHIST
Explore Geranylgeranyl transferase type-1 subunit beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets